CTLA4 and hepatocellular carcinoma: For example, combination of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, tremelimumab, and PD-1 inhibitor, durvalumab, was approved for treating patients with unresectable hepatocellular carcinoma in 2022 [21, 22].